Aviceda

Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent

Retrieved on: 
Monday, October 23, 2023
Technology, Research, Diabetes, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Patient, SIGLEC, Macrophage, Injection, Microglia, Geographic atrophy, Inflammation, Factor, Senior, Pharmacokinetics, Growth, Clinical trial, American Academy, GA, American Academy of Ophthalmology, Aviceda, Safety, Therapy, Pharmaceutical industry, Ophthalmology

By repolarizing these immune cells to a resolution state, AVD-104 effectively reduces inflammation.

Key Points: 
  • By repolarizing these immune cells to a resolution state, AVD-104 effectively reduces inflammation.
  • Additionally, it enhances the activity of complement factor H, a crucial regulator of the complement cascade, to better regulate overamplification of the alternative complement cascade.
  • We are excited by our data to date and look forward for our larger clinical trial to start next month.”
    The SIGLEC U.S.
  • Part 1 of the trial is a multi-center, open label safety and dose escalation study that enrolled 30 participants.

Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration

Retrieved on: 
Monday, September 25, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Clinical Trials, Infection, SIGLEC, AMD, Aviceda, Safety, Retinal vasculitis, Cohort, Clinical trial, Geographic atrophy, GA, Inflammation, Part, Disulfiram-like drug, Panel, MD, Physician, Patient, Modulation, Nanoparticle, Therapy, Society, Choroidal neovascularization, Pharmaceutical industry, Macrophage

19:00-19:30, Mohamed Genead, MD, Panel 8 - Novel Therapeutics for Geographic Atrophy: How do we measure success for physicians, patients, and payers?

Key Points: 
  • 19:00-19:30, Mohamed Genead, MD, Panel 8 - Novel Therapeutics for Geographic Atrophy: How do we measure success for physicians, patients, and payers?
  • The study evaluated patients with GA secondary to AMD from Cohorts 1 and 2 in the Phase 2/3 (Part 1) SIGLEC trial.
  • Notably no drug related inflammation, retinal vasculitis, choroidal neovascularization, infection, or optic nerve abnormalities were seen in any eyes.
  • Though the SIGLEC trial recently began in June of this year, Aviceda has already completed the dose-escalation enrollment for all cohorts in Part 1.

Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings

Retrieved on: 
Wednesday, July 19, 2023
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Thomas Jefferson University, AMD, Geographic atrophy, SIGLEC, Therapy, Safety, Society, GA, ASRS, Aviceda, Pharmaceutical industry, Ophthalmology

“We are excited about Aviceda's presence at ASRS this year.

Key Points: 
  • “We are excited about Aviceda's presence at ASRS this year.
  • AVD-104 was engineered with dual mechanism of action to target both the cellular immune dysfunction and complement implicated in AMD progression.
  • “We look to usher in a new paradigm for safer and effective treatment of GA associated with AMD,” said Mohamed Genead, M.D., Chief Executive Officer & Co-Founder, Aviceda Therapeutics.
  • “I am excited to present the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, in the Phase 2 SIGLEC Trial

Retrieved on: 
Thursday, June 1, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Clinical Trials, SIGLEC, Macrophage, AMD, Geographic atrophy, Hope, GA, System, Fibrosis, MD, Patient, Associate, Therapy, Neurology, Pharmaceutical industry, Aviceda

This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • “I am honored to be the first to dose a new agent that we hope will usher in a generation of safe treatments for GA with better outcomes than were ever possible before,” said Dr. Abbey.
  • “AVD-104 is a potentially transformative targeted approach for patients with GA due to AMD,” said David Callanan, M.D., Chief Medical Officer of Aviceda.
  • Based on this dual mechanism and the exquisite selectivity and preclinical potency of AVD-104, we believe it could provide a profound benefit for patients in dire need of new therapies.

Aviceda Therapeutics Appoints Biopharma and Business Senior Executive Patrick Johnson, PhD, to its Board of Directors

Retrieved on: 
Tuesday, May 16, 2023
Health, Other Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Macular degeneration, Allergan, Geographic atrophy, Retina, GA, Inflammation, Doctor of Philosophy, MD, Patient, Entrepreneurship, Therapy, Pharmaceutical industry, Aviceda

Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.

Key Points: 
  • Patrick is an accomplished business leader and entrepreneur with a proven track record of enabling pharmaceutical and biotechnology companies to maximize the value of their brands and realize the potential of their innovations.
  • “We are thrilled to welcome Patrick to Aviceda’s board of directors as we advance our pipeline through key milestones in 2023 and beyond,” said Mohamed A. Genead, MD, CEO & President, Co-Founder of Aviceda Therapeutics.
  • Previously, he gained exceptional sell-side and buy-side transactional experience as head of business development for eye care and drug delivery at Allergan.
  • “I look forward to working alongside this dynamic team and advancing a diverse pipeline through development and into commercialization.”

Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)

Retrieved on: 
Monday, April 10, 2023
Research, Neurology, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Yale Cancer Center, Faculty, Star Trek: 25th Anniversary (computer game), Good, Partnership, Drug development, Therapy, Genomics, Clinical trial, Cancer, Digital health, Patient, Laboratory, Ecosystem, Conference, Data science, Pharmaceutical industry, Aviceda, Medicine

Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s).

Key Points: 
  • Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s).
  • This revolutionary technology was made possible only through collaborative research on the island of Ireland.
  • The founding of Aviceda Glycotech Ltd, an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s, based in Northern Ireland, highlights US-Ireland translational research collaborations which are a direct legacy of the Good Friday Agreement.
  • Aviceda Glycotech looks forward to this collaboration aimed at developing the next generation of cancer checkpoint immune therapeutics in Belfast.

Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration

Retrieved on: 
Thursday, April 13, 2023
Research, Technology, FDA, Clinical Trials, Nanotechnology, Biotechnology, Pharmaceutical, Health, Optical, Science, Macrophage, AMD, Geographic atrophy, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, GA, Food, Macular degeneration, Patient, Disease, Pharmaceutical industry, Aviceda

The Phase 2 SIGLEC trial is expected to begin in Q2 2023.

Key Points: 
  • The Phase 2 SIGLEC trial is expected to begin in Q2 2023.
  • “The AVD-104 IND clearance marks an important milestone for Aviceda as we continue our track record of execution as the leader in the glycome field.
  • “I am very excited to bring the power of our glyco-biology based technology platform to address the significant unmet medical needs in patients with macular degeneration.
  • This is the first step in bringing a novel and differentiated therapy to these patients,” said David Callanan, M.D., Chief Medical Officer of Aviceda.

Aviceda Announces 3 Presentations about AVD-104, its Lead Glyco-mimetic Nanoparticle, As a Novel Treatment for Geographic Atrophy from Macular Degeneration, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, April 2023

Retrieved on: 
Monday, April 3, 2023
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Retina, Sial, ARVO, University, Therapy, University of California, Irvine School of Medicine, AMD, Geographic atrophy, GA, Cell, Doctor of Philosophy, System, Patient, Nanoparticle, Microglia, Growth, Disease, Pharmaceutical industry, Environmental remediation, Vaccine, Macrophage, Aviceda, Ophthalmology, MD, Medicine

Detailed results from each of these three studies will be reported at the conference.

Key Points: 
  • Detailed results from each of these three studies will be reported at the conference.
  • “We are excited to present our data at ARVO this year.
  • Blocking complement alone removes a stimulus for these cells which slows down but does not stop this cellular process.
  • Modulation of Macrophages and Complement Dysfunction in Nonexudative Age-Related Macular Degeneration Utilizing a Sialic-acid Coated Nanoparticle, Baruch Kuppermann, MD, PhD.

Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration (AMD)

Retrieved on: 
Monday, March 20, 2023
Biotechnology, FDA, Health, Pharmaceutical, Optical, GLP, Good laboratory practice, AMD, Toxicity, GA, Fibrosis, Investigational New Drug, Animal, MD, Patient, Rabbit, Entrepreneurship, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Eye disease, Safety, Pharmaceutical industry, Aviceda

Aviceda previously announced the successful completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies that showed positive safety data for multiple well-tolerated doses of AVD-104.

Key Points: 
  • Aviceda previously announced the successful completion of IND-enabling Good Laboratory Practice (GLP) toxicity studies that showed positive safety data for multiple well-tolerated doses of AVD-104.
  • This included dose-range finding studies in non-human primates (NHPs) and rabbits (80 total animals), to support continued development and the initiation of human clinical trials.
  • “With only one currently approved therapy for the treatment of GA, there is still a significant unmet medical need for patients with this condition.
  • We anticipate beginning our Phase 2 trial as soon as possible after FDA review.

Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primates

Retrieved on: 
Monday, December 5, 2022
Biotechnology, Technology, Other Health, Health, General Health, Pharmaceutical, Optical, Research, Nanotechnology, Science, Clinical Trials, Therapy, Rabbit, CNV, Phase, Drug development, Geographic atrophy, Fibrosis, GA, Fast track (FDA), AMD, Aviceda, Patient, Animal, GLP, FDA, Neurology, Ophthalmology, Safety, Eye, Good laboratory practice, Pharmaceutical industry, IND

Importantly, the results further validate the Companys technology platform that is utilized throughout Avicedas pipeline.

Key Points: 
  • Importantly, the results further validate the Companys technology platform that is utilized throughout Avicedas pipeline.
  • The outcome, therefore, has positive read-through implications across each of Avicedas therapeutic applications such as fibrosis, neurology, and immunology.
  • GLP-Tox studies were completed in two species which demonstrated excellent safety and no signs of any intra-ocular inflammation.
  • In addition to AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and other therapeutic areas such as neurology, fibrosis, and immunology.